Stimulation of the Jun NH 2 -terminal kinase/stress-activated protein kinase (JNK/SAPK) and the p38 mitogen-activated protein kinase (p38/MAPK) is part of the stress-related signal transduction pathways conveying signals from the cell surface into the nucleus in order to initiate programmes of gene expression. Here, it was shown that infection by varicella-zoster virus (VZV) caused a 34-fold increase in activation of JNK/SAPK in the early phase of infection and a 2-fold increase in activation of p38/MAPK in the later phase. The phosphorylation of downstream targets c-Jun and ATF-2 was also increased; subsequent cascades to induce pro-inflammatory responses were significantly activated whereas cascades to activate apoptotic events were not. In the late phase of infection, both JNK/SAPK and p38/MAPK activities were reduced to basal levels. The use of specific inhibitors demonstrated that inhibition of JNK/SAPK resulted in a 2-fold increase in VZV replication whereas a strong decrease in virus replication was observed after inhibition of p38/MAPK. In contrast, constitutive activation of JNK/SAPK resulted in a decline in VZV replication. Blocking gene expression by treating cells with actinomycin D or cycloheximide prior to infection resulted in activation of neither JNK/SAPK nor p38/MAPK. It was assumed that the presence of tegument proteins was not sufficient to activate stress pathways, but that expression of viral genes was necessary. This suggests that activation of stress pathways by VZV infection represents a finely regulated system that activates cellular transcription factors for transregulation of VZV-encoded genes, but prevents activation of cellular defence mechanisms.
INTRODUCTION
Varicella-zoster virus (VZV), a human pathogenic neurotropic alphaherpesvirus, is the aetiological agent of two distinct clinical exanthemas: varicella (chicken pox), which results from primary infection, and herpes zoster (shingles), a disease caused by the reactivated latent virus. VZV is the smallest of the alphaherpesviruses. Its 125 kbp genome contains at least 70 unique open reading frames (ORFs) and three duplicated genes (reviewed by Ruyechan & Hay, 2000) . Following entry, uncoating and transport, virus replication takes place inside the nucleus of the infected cell starting with the transcription of immediate-early (IE) genes, the products of which act as transregulatory proteins orchestrating the expression of early (E) and late (L) genes (for an overview, see Sadzot-Delvaux et al., 1999) .
The cell's ability to sense external stimuli and to react by initiating a programme of gene expression often involves propagation of a cell-surface-initiated signal along specific pathways of protein kinases whose targets are nuclearacting transcription factors. Factors such as the type of stimulus, its duration and the cell type can influence whether the transduced signals are interpreted as growth stimulatory, growth inhibitory or apoptotic events causing cell stress (Ip & Davis, 1998; Kyriakis et al., 1995; Robinson & Cobb, 1997; Whitmarsh & Davis, 1996) . Many of these stimuli are mediated through the activation of distinct mitogen-activated protein kinase (MAPK) cascades. The best characterized of these are the extracellular-signalregulated kinase (ERK), the c-Jun NH 2 -terminal kinase/ stress-activated protein kinase (JNK/SAPK) and the p38/ MAPK pathways (Kyriakis & Avruch, 1996; Seger & Krebs, 1995) . While the ERK pathway is activated by proliferative stimuli, UV irradiation, environmental stress and proinflammatory cytokines stimulate the JNK/SAPK and p38/ MAPK cascades. Although there is coordinated regulation of JNK/SAPK and p38/MAPK, they have distinct upstream activators. p38/MAPK is activated by MAPK kinases (MKKs) 3 and 6, whereas MKK 4 and MKK 7 activate both JNK/SAPK and p38/MAPK Lawler et al., 1997) .
JNK/SAPK and p38/MAPK phosphorylate a number of transcription factors, including c-Jun, which is specifically phosphorylated by JNK/SAPK, and ATF-2, which is phosphorylated by both JNK/SAPK and p38/MAPK (Derijard et al., 1994; Gupta et al., 1995; Kyriakis et al., 1994) . c-Jun binds the 12-O-tetradecanoate-13-acetate response element (AP-1/TRE), and the so-called cAMP response element (ATF/CRE) is recognized by ATF-2 (Angel et al., 1987; Castellazzi et al., 1991; Montminy, 1997; Northrop et al., 1993) . Recently, we identified a large number of AP-1/TRE and ATF/CRE sites inside VZV promoters .
Viruses are ultimately dependent upon the host cell for their replication. Because they reorganize or utilize various cellular functions, it seems likely that viruses would take advantage of pre-existing signalling pathways to induce cellular and/or viral gene expression to promote virus replication. Recent reports have shown that several viruses can induce the activation of MAPK pathways in infected cells, such as human immunodeficiency virus type 1 (Kumar et al., 1998; Li et al., 1997) , human cytomegalovirus (Rodems & Spector, 1998) , echovirus (Huttunen et al., 1998) , Sindbis virus (Nakatsue et al., 1998) and herpes simplex virus type 1 (HSV-1) (McLean & Bachenheimer, 1999; Zachos et al., 1999) . However, the precise role of MAPK in the replication of viruses remains unclear. No data concerning the activation of MAPK pathways during the replication cycle of VZV are available.
This investigation was initiated to determine whether MAPK plays a role in the replication of VZV. We report that VZV induced the activation of MAPKs such as JNK/ SAPK and p38/MAPK in the early phase of infection. The use of specific inhibitors or activators of MAPKs resulted in severe variations in VZV replication. We also showed that the JNK/SAPK and p38/MAPK downstream targets were activated, but subsequent cascades leading to JNK/ SAPK-mediated apoptotic events failed to be notably stimulated, whereas a strong increase in IL6 secretion was observed as a consequence of p38/MAPK activation. Furthermore, we demonstrated that the activation of stress pathways depended on VZV gene expression.
METHODS
Cells and viruses. MEWO cells (ECACC 93082609) were grown as described previously . VZV strain Ellen (ATCC VR-586) was propagated by passage of infected cells showing 80 % cytopathic effect on to uninfected monolayers at a ratio of 1 : 15.
Reagents and cell treatment. SB202190 (an inhibitor of p38/ MAPK), anisomycin (an activator of JNK/SAPK) and the JNK inhibitor I (L-form; cell-permeable, biologically active peptide consisting of HIV-TAT 48-57 -PP-JBD 20 ) were purchased from Calbiochem. Cells were treated with SB202190 or JNK inhibitor at varying concentrations for 30 min prior to infection; treatment with anisomycin (activator of JNK/SAPK) was carried out for 45 min before infection. Actinomycin D (ActD) and cycloheximide (CHX) were purchased from Sigma-Aldrich; cell treatment was performed 1 h prior to infection using 0?5 mg ActD ml 21 and 10 mg CHX ml 21 .
Whole-cell and nuclear-extract preparation and immunoblotting. Nuclear protein extracts for the transcription factor assay were prepared using the Nuclear Extract kit (Active Motif) according to the manufacturer's instructions.
To prepare whole-cell extracts at the indicated time points, cells were harvested in PBS supplemented with 10 mM PMSF and protein concentrations were determined by the Bradford method. Samples were then dissolved in SDS sample buffer (40 mM Tris/HCl, pH 6?8, 2 % SDS, 280 mM b-mercaptoethanol, 10 % glycerol, 0?01 % bromophenol blue).
Preparation of nuclear extracts for immunoblotting was done as described by Andrews & Faller (1991) . Immunoblotting of 25 mg of the respective protein extract (whole-cell or nuclear extract) was done as described previously (Rahaus & Wolff, 2000) . Protein detection was done using anti-JNK/SAPK, anti-p38/MAPK, anti-PARP (all from New England Biolabs), anti-VZV pIE4, anti-VZV pE29 and anti-VZV pIE63 (kindly provided by P. Kinchington, R. Cohrs and B. Rentier, respectively), anti-gE (Biodesign International) and anti-USF2 (Santa Cruz) polyclonal antibodies. All antibodies were diluted 1 : 1000 in 5 % BSA, 16 TBS, 0?1 % Tween 20 and detected using an alkaline phosphatase-conjugated secondary antibody (Santa Cruz; diluted 1 : 1000) and NBT/BCIP (ICN). IL6 ELISA. The high-sensitivity human IL6 ELISA kit (Diaclone Research) was used according to the manufacturer's instructions. Briefly, 100 ml cell culture supernatant from VZV-infected cells was taken at various time points post-infection (p.i.) and introduced into the assay. Supernatants were then reacted with a biotinylated anti-IL6 antibody for 3 h. After washing, streptavidin-HRP was added, followed by a colorimetric reaction. A 450 was determined using a plate spectrophotometer and IL6 concentrations were calculated based on a standard curve.
RESULTS
Variations in VZV replication after blocking of p38 MAPK or JNK/SAPK We first examined the presence of the key players in the MAPK pathways, JNK/SAPK and p38/MAPK, in VZVinfected cells. Whole-cell lysates of infected (48 h p.i.) and mock-infected cells were used for immunoblotting. Specific bands of 44 and 56 kDa for JNK1 and JNK2, as well as 43 kDa for p38/MAPK, were found in protein lysates of both infected and mock-infected cells (Fig. 1a, b) . To monitor the infection, the presence of VZV gE was also analysed. A band of 110 kDa was found in the protein extract derived from infected cells (data not shown). . At 24 h p.i., the amount of progeny virus was determined in an area of 2 cm 2 by VZV plaque assay using triplicate samples. For each test series, the number of plaques in untreated cells was used as a control and taken as 100 % (corresponding to at least 150 plaques). Results are given as means±SD.
To determine whether activation of MAPKs plays a role in the replication of VZV, we examined the impact of these kinases on progeny virus production in virus-infected MEWO cells by inhibiting MAPKs. In triplicate experiments, cells were infected with VZV in the presence of the highly specific JNK inhibitor I (Bonny et al., 2001 ) and SB202190, a potent and selective inhibitor of p38/MAPK (Manthey et al., 1998) , at different concentrations based on the findings of Hirasawa et al. (2003) and determined the amount of virus replication by performing plaque assays at 24 h p.i. Both inhibitors prevent the phosphorylation of the respective target. The effectiveness of inhibition was monitored using FACE assays. At the higher concentrations of each inhibitor, the corresponding MAPK was completely inhibited (data not shown).
MEWO cells were treated with medium containing 5 or 20 mM JNK inhibitor I for 30 min before infection. At a concentration of 5 mM, we found an increase in VZV replication up to 149?1 %, while using 20 mM inhibitor increased the replication efficiency up to 193?9 % compared with virus progeny in untreated cells (taken as 100 %) (Fig. 1c) . Contrasting results were obtained after inhibition of p38/MAPK by SB202190, with a reduction in the replicative activity to 55?78 % (using 10 mM inhibitor) and 34?68 % (using 30 mM inhibitor) compared with untreated cells (Fig. 1d) . Inhibition of the ERK1/2 pathway did not affect VZV replication (data not shown).
Activation of JNK/SAPK and p38 MAPK during the replicative cycle
We next focused on the possible activation of JNK/SAPK and p38/MAPK during the replicative cycle. VZV-infected MEWO cells at early and late times p.i. were used for FACE assays to monitor both the early phase of infection and long-term events. The FACE system allowed the quantification of activated JNK/SAPK and p38/MAPK in a high throughput series; results from three independent infection series are shown in Fig. 2 . A 2-fold increase in activation of phosphorylated JNK/SAPK was observed at 1 h p.i., followed by a peak 34-fold increase in activation at 6 h p.i. The level of JNK/SAPK phosphorylation subsequently fell to its basal level as determined at 0 h p.i. and remained constant (Fig. 2a) . In contrast, phosphorylation of p38/MAPK decreased between 1 and 6 h p.i. from its basal level as determined at 0 h p.i. and showed only a 1?8-fold peak increase in activation at 12 h p.i. (Fig. 2a) . A corresponding experiment was performed to determine the total amounts of JNK/SAPK and p38/MAPK protein. In both cases, we observed a decrease in protein accumulation in the early phase of infection followed by an increase, peaking at 6 h p.i. JNK/SAPK total protein increased up to 380 %, whereas accumulation of p38/MAPK protein only reached 125 %. Following these peaks, the accumulation levels of both proteins decreased and remained constant at 60-75 % from 12 to 48 h p.i. compared with the protein level at 0 h p.i., which was taken as 100 % (Fig. 2b) . As a control for infection, the presence of VZV IE63 was monitored by immunoblotting of whole-cell lysates derived at the respective time points (Fig. 2d) . To ensure that the observed effects were specific and did not reflect an overall increase in protein concentration, the cellular protein USF2 was also analysed. It is known that expression of USF2 is not influenced by VZV infection ; expression levels of USF2 remained unchanged (Fig. 2d) .
Propagation of JNK/SAPK and p38/MAPK signals for activation of downstream cascades during the replicative cycle
To confirm that activation of JNK/SAPK and p38/MAPK following VZV infection truly resulted in activation of their respective downstream targets c-Jun and ATF-2, respectively, the phosphorylation of these two transcription factors was measured in infected cells by transcription factor assays. In triplicate experiments, 15 or 12 mg nuclear extract prepared from VZV-infected cells and harvested at different time points was used for a binding reaction to immobilized oligonucleotides containing an AP-1/TRE element (c-Jun binding) or an ATF/CRE element (ATF-2 binding), respectively. Using a phospho-specific anti-c-Jun antibody, we obtained a steady increase in c-Jun phosphorylation starting at 1 h p.i. and reaching a plateau of elevated activation between 5 and 6 h p.i. In the subsequent phase of the replicative cycle, the level of c-Jun phosphorylation dropped off, returning to the basal level measured at 0 h p.i. by 36 h p.i. (Fig. 3a) .
With regard to phosphorylation of ATF-2 as a target mainly of p38/MAPK, but also of JNK/SAPK, we found two peaks of activation during VZV infection. The first occurred between 2 and 3 h p.i., reaching a plateau of activation of 235 % (2 h p.i.) and 233 % (3 h p.i.) compared with the basal ATF-2 activity measured at 0 h p.i. and taken as 100 %. This elevated ATF-2 phosphorylation corresponded to the increased activation of JNK/SAPK in the early phase of infection. The second peak of ATF-2 activation was found at 12 h p.i., reaching a level of 249 % (Fig. 3b) . This was the time point at which we detected the highest activation level of p38/MAPK (see Fig. 2b ). Control experiments using nuclear extracts of both JNK/ SAPK-and p38/MAPK-induced cells, as well as competitive oligonucleotides with wild-type or mutated binding sites of the respective factors, confirmed the efficiency and specificity of the system (data not shown). Infection was monitored by detection of VZV IE63 (Fig. 3c) . Cellular USF2 was also analysed to ensure that the observed effects were specific and did not reflect an overall increase in protein concentration. Expression levels of USF2 remained unchanged (data not shown). At all time points, the 116 kDa band of the full-length protein was detected (Fig. 4a) In addition to ATF-2 expression, a further biological consequence of p38/MAPK activation is the production of inflammatory and pyrogenic cytokines. IL6 belongs to this group of cytokines that participate in inflammatory and febrile responses accompanying viral infections. Expression of IL6 depends on the presence of a functional MKK3Rp38/MAPKRMAPKAP kinase 2 signalling cascade (Beyaert et al., 1996; Iordanov et al., 2000) . To address this question, a high-sensitivity IL6 ELISA was performed using supernatants from uninfected cells and from cells infected with VZV for 12 h, the time point of highest p38/MAPK activity. Experiments were done in triplicate and the results are shown in Fig. 4(b) . We found a strong increase in IL6 secretion at 12 h p.i. compared with the basal level at 0 h p.i. To investigate whether this increase in IL6 secretion depended on VZV-mediated activation of the corresponding p38/MAPK pathway, we inhibited p38 phosphorylation with SB202190 prior to infection. No secretion of IL6 was found (Fig. 4b) . Detection of USF2 in lysates derived from cells whose supernatant was introduced into the ELISA by immunoblotting confirmed that the increase in IL6 expression did not result from an overall increase in protein expression (Fig. 4c) . Based on the fact that p38/ MAPK inhibition led to reduced virus yields, another control was added to monitor the possible effects of SB202190 on the induction of apoptosis in MEWO cells. No PARP cleavage was detected (Fig. 4c ).
These data indicated activation of c-Jun and ATF-2 in the early phase of VZV infection. The time course of phosphorylation corresponded to that described above for JNK/ SAPK phosphorylation, affecting both c-Jun and ATF-2. p38/MAPK affected ATF-2 activity in the later phase of the infection. Moreover, these data suggested that activation of these MAPKs as a consequence of infection led to a propagation of the signal to downstream targets. No significant activation of JNK/SAPK-mediated apoptosis was detected, but there was a remarkable increase in IL6 secretion.
Variations in virus replication after activation of JNK/SAPK
We compared syncytium formation as a marker of virus replication with the levels of phosphorylation of JNK/ SAPK and p38/MAPK after treatment of cells with the corresponding inhibitor or anisomycin. At subinhibitory concentrations, anisomycin strongly activates JNK/SAPK and p38/MAPK in mammalian cells. If used at inhibitory concentrations (10 mg ml
21
), anisomycin is known to act Fig. 3 . Phosphorylation levels of c-Jun and ATF-2 as downstream targets of JNK/SAPK and p38/MAPK. Determination of c-Jun (a) and ATF-2 (b) phosphorylation levels by transcription factor assay during the VZV infectious cycle. Nuclear protein extract (15 mg for c-Jun and 12 mg for ATF-2), prepared at each indicated time point p.i., was introduced into the assays, and after processing according to the assay instructions reacted with an anti-phospho-specific antibody. c-Jun or ATF-2 activation detected at 0 h p.i. was taken as 100 %. All experiments were done in triplicate and results are given as means±SD. (c) Control experiment to monitor infection by immunoblotting samples of the above-mentioned nuclear extracts followed by detection of VZV IE63.
as an inhibitor of protein synthesis at the translational step (Cano et al., 1994; Hazzalin et al., 1998) . Plaque formation and phosphorylation of JNK/SAPK or p38/MAPK in untreated, VZV-infected cells were taken as 100 %; all experiments were done in triplicate. As shown above, after treatment of cells with JNK inhibitor, the number of VZV plaques increased 2-fold and no phosphorylation of JNK/ SAPK was detected (Fig. 5a) . Using anisomycin at the subinhibitory concentration of 50 ng ml
, we detected activation of JNK/SAPK up to 230?4 %, whereas the number of viral plaques decreased to 44?83 %. This effect was intensified when 500 ng anisomycin ml 21 was used: JNK phosphorylation increased to 747?6 %, while the plaque number decreased to 7?37 % (Fig. 5a ). These results revealed that activation of JNK/SAPK caused strong inhibition of the replication of VZV. Different data were obtained when the number of VZV plaques was compared with the level of p38/MAPK phosphorylation. Again, inhibition of p38 using SB202190 (30 mM) led to a loss of p38/MAPK phosphorylation, as well as a reduction in plaque number to 35 %. Surprisingly, neither 50 nor 500 ng anisomycin ml 21 resulted in any increase in p38/MAPK phosphorylation in MEWO cells (Fig. 5b) . The number of viral plaques matched that found when virus replication versus JNK/SAPK phosphorylation was investigated.
In conclusion, the consequence of activation of JNK/SAPK was a significant reduction in VZV replication. Repression of virus replication depended on the level of JNK/SAPK phosphorylation. No such effect seemed to be related to p38/MAPK.
Importance of viral gene expression for the activation of JNK/SAPK and p38/MAPK
The absence of significant JNK/SAPK and p38/MAPK activities at a very early time after infection led us to assume that neither VZV-caused induction of a receptor-mediated signal cascade nor the presence of VZV tegument proteins . (b) Analysis of IL6 secretion as a consequence of increased p38/MAPK activation at 12 h p.i. An increase in IL6 secretion was observed at 12 h p.i., while inhibition of p38/MAPK activity by SB202190 prior to infection resulted in the loss of IL6 production. Experiments were done in triplicate and results are given as means±SD. (c) Control experiments to monitor the effects of SB202190 on the induction of apoptosis, which could falsify IL6 data, showing immunoblotting of whole-cell lysates derived from cells treated with 30 mM SB202190 and reacted with an anti-PARP antibody. The positive controls were as described in (a) (upper panel) and a control for sample loading (lower panel), which comprised immunoblotting of whole-cell lysates derived from the time points indicated in (b) and reacted with an anti-USF2 antibody.
was sufficient to activate these two MAPKs, but that the expression of viral genes or virus-mediated cellular gene expression was necessary. To confirm this hypothesis, we performed cell-based ELISAs to measure JNK/SAPK and p38/MAPK phosphorylation in cells that had been treated with CHX (10 mg ml 21 ) prior to infection to block gene expression. In order to determine whether accumulation of transcribed but not translated viral and cellular mRNAs caused a stress situation that triggered the activation of JNK/SAPK or p38/MAPK, cells were also treated with ActD (0?5 mg ml
21
) to inhibit gene expression at the transcriptional step. Fig. 6(a) shows that, as a consequence of the cell treatment, expression of VZV E and L genes, represented here by the products of ORF29 (single-stranded DNAbinding protein) and ORF68 (gE), respectively, was in fact inhibited, whereas components of the viral tegument of input virions, represented by the product of the IE gene ORF4, were still detectable.
Neither CHX nor ActD showed any activating effect on JNK/SAPK or p38/MAPK in uninfected control cells (Fig. 6b, c) . In addition, after infection of cells treated with CHX or ActD, no activation of JNK/SAPK or p38/ MAPK was measured. Only infected but untreated cells showed the expected elevated JNK/SAPK and p38/MAPK activities when analysed at the time p.i. showing the strongest activation (Fig. 6b, c ; compare with Fig. 2 ).
Based on these findings, we concluded that virus entry and release of the tegument proteins is not sufficient to activate stress-related MAPKs. Expression of viral genes or VZVmediated expression of cellular genes seems to be required.
DISCUSSION
Viral infections are known to result in activation of intracellular signalling, which can affect cellular function and virus replication. Many viruses have been shown to induce MAPK pathways, even though the significance of these inductions still remains unknown (Benn et al., 1996; Bruder & Kovesdi, 1997; Ludwig et al., 2001; Pleschka et al., 2001; Popik & Pitha, 1998; Rodems & Spector, 1998) . Recently, we demonstrated that infection with VZV led to an increase in transcription of the AP-1 components c-Jun, c-fos and ATF-2, which are MAPK downstream targets .
Signals leading to MAPK activation are often generated at the cell surface when receptors bind to their appropriate ligand. Some reports have shown that binding of a virus to a cell-surface receptor mimicking normal ligand-receptor events activates downstream pathways. Simian immunodeficiency virus activates ERK, JNK/SAPK and p38, depending on cell type and receptor (Popik & Pitha, 1998) . Upon binding to the surface of permissive cells, cytomegalovirus generates intracellular signals that induce the translocation and activation of NF-kB (Sambucetti et al., 1989; Yurochko et al., 1997) . In this study, we showed that VZV infection also resulted in short-term activation of upstream MAPK pathways. In the early phase of infection, a 34-fold and a 2-fold elevation of JNK/SAPK and p38/MAPK phosphorylation, respectively, were detected. Our data also indicated a block in both pathways after their peaks of phosphorylation and, in consequence, activity of the downstream targets c-Jun and ATF-2 also decreased. The fact that two peaks of ATF-2 activation were found can be explained by the postponed activation of JNK/SAPK and p38/MAPK. However, the mechanisms leading to the repression of MAPK activities remain undefined. We also observed weak induction of JNK/SAPK within the first hour of infection, corresponding to interactions of viral glycoproteins located on both the virus envelope and the infected-cell surface with receptors of as yet uninfected cells. These data contrast with the findings of McLean & Bachenheimer (1999) , who did not detect any activation within this early attachment and penetration phase of HSV infection. However, following VZV penetration, strong activation began no earlier than 4 h p.i. for JNK/SAPK and 5 h p.i. for p38/MAPK, which is compatible with data from HSV during the corresponding phase of infection (McLean & Bachenheimer, 1999) .
Activation of JNK/SAPK and p38/MAPK could be a nonspecific response by the cell, but results from experiments using CHX-or ActD-treated cells argue against this interpretation. The data showed that expression of viral genes or, alternatively, virus-mediated expression of cellular genes is necessary to induce JNK/SAPK and p38/MAPK phosphorylation. Due to the onset of JNK/SAPK and p38/ MAPK activation that occurs at 4 and 5 h p.i., respectively, it is likely that expression of VZV-encoded genes is the necessary event for initiation of MAPK activation. By this time, expression of IE and E genes has started. IE proteins have already reached high levels of accumulation and have ample time to perform their functions. The presence of viral tegument proteins or the capsid seemed not to be sufficient to achieve this activation.
Experiments using highly specific inhibitors provided evidence that both JNK/SAPK and p38/MAPK have substantial but opposing effects on VZV replication. Blocking the ability of JNK/SAPK to act on its nuclear substrates resulted in increased VZV replication, whereas inhibition of p38/MAPK led to a reduction in virus replication. It is known that promoters of all kinetic classes of VZV genes ) and CHX (10 mg ml "1 ). To monitor ActD-and CHX-mediated activation of JNK/SAPK, uninfected cells were analysed (VZV neg.) and compared with untreated and uninfected cells (labelled C). In treated and infected cells, no activation of JNK/SAPK was found (VZV pos.). Only untreated cells analysed at a previously determined time point (see Fig. 2 ) showed significant phosphorylation of JNK/SAPK (column C*). (c) The phosphorylation state of p38/MAPK was analysed as described in (b). Again, activation of p38/MAPK was found only in infected but untreated cells (column C*). Experiments presented in (b) and (c) were done in triplicate and results are given as means±SD.
contain cognate binding sites for a variety of cellular transcription factors, e.g. Oct-1, USF, Sp1, NF-kB and AP-1 (Ito et al., 2003; Kinchington et al., 1994; Meier et al., 1994; Rahaus & Wolff, 2000) , which are all targets of upstream signalling pathways. Downregulation of the expression of AP-1 affects the efficiency of transactivation and effectiveness of replication . Similar reports underlining the importance of specific cellular components for herpesviral gene regulation have described the physical interaction of VZV IE62 with Sp1 or USF (Peng et al., 2003; and Patel et al. (1998) showed that blocking HSVmediated translocation of NF-kB into the nucleus reduced virus yields by 90 %. JNK/SAPK is known to be responsible for complex and cell-type-specific effects, since its activation in different conditions and cell types correlates with proliferation, oncogenic transformation and apoptosis (Ip & Davis, 1998; Whitmarsh & Davis, 1996) . No significant activation of PARP cleavage as a marker of apoptotic response after activation of the upstream cascade JNK/SAPKR c-JunR(Bax/Bak/Bid)R(cytochrome c/caspase 9/Apaf-1)R caspase 3 (Li et al., 2004 , and references therein) was detected in MEWO cells, leading to different assumptions: firstly, that the host defence induction triggered by VZV is not strong enough to activate apoptotic pathways and, secondly, that VZV is able to modulate the activation of apoptotic events in order to enhance its survival and spread. The second hypothesis is substantiated by the report of Hood et al. (2003) showing differences in the apoptotic responses to VZV depending on the cell type. We propose that JNK/SAPK, once activated, could phosphorylate cellular or viral transcription factors to enhance the expression of VZV-encoded genes but is shut down afterwards by an as yet unknown mechanism to suppress the activation of cellular defence systems and the apoptotic response. The activation of ATF-2 downstream of p38/ MAPK activation seems to be necessary for the expression of VZV genes. This is substantiated by the fact that inhibition of p38/MAPK and knockout of ATF-2 transcription led to a severe decrease in VZV replicative activity. In contrast to JNK/SAPK and p38/MAPK, ERK1/2 seems not to play an important role in the VZV replicative cycle since its inhibition did not affect the production of virus progeny. HSV also fails to activate ERK (McLean & Bachenheimer, 1999) . Moreover, several lines of evidence exist to support a role for MEKs and ERKs in the inhibition of IL6 activity. However, results shown in this report demonstrated that infection of cells with VZV led to an increase in IL6 secretion, indicating that VZV does not seem to cause activation of the MEK/ ERK pathway leading to inhibition of IL6.
IL6 production was blocked after inhibition of the p38/ MAPK pathway. The role of the MKK3Rp38/MAPKR MAPKAP kinase 2 signalling cascade in the production of IL6 is well established (Miyazawa et al., 1998) . Iordanov et al. (2000) reported a similar activation of IL6 secretion after infection of cells with encephalomyocarditis virus and postulated a possible role for proinflammatory cytokines in combating viruses. Our results demonstrated some similarities in MAPK activation patterns, and previous data from our laboratory showing that neither the protein kinase R nor RNase L pathways for host defence are activated after VZV infection (Desloges et al., 2004) support the hypothesis that activation of p38/MAPK and JNK/SAPK after viral infection may represent a new host-defence mechanism. Moreover, activation of cellular signalling pathways is mainly achieved after expression of VZV components and triggers the production of cellular transcription factors, which have important functions in transactivating VZV genes. The cellular defence systems and apoptotic responses that are activated by the same pathways may be repressed by as yet unknown mechanisms to ensure virus replication. Further studies are necessary to investigate this virus-host interaction more precisely.
